Nucleoside

Type: Keyphrase
Name: Nucleoside
First reported 35 mins ago - Updated 35 mins ago - 1 reports

Methods for identifying RNA segments bound by RNA-binding proteins or ribonucleoprotein complexes

The present invention relates to a method for identifying a binding site on an RNA transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living ... [Published Free Patents Online - 35 mins ago]
Entities: RNA, Nucleoside, cDNA, Mutation
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Metal-Ion-Mediated Base Pairing between Natural Nucleobases and Bidentate 3,5-Dimethylpyrazolyl-Substituted Purine Ligands

The potential of three modified purine bases, namely, 6-(3,5-dimethylpyrazol-1-yl)purine, 2-(3,5-dimethylpyrazol-1-yl)hypoxanthine, and 2-(3,5-dimethylpyrazol-1-yl)adenine, for metal-ion-mediated base pairing within an oligonucleotide environment has ... [Published Journal of Organic Chemistry - 15 hours ago]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

WuXi AppTec Information Session

Home › UMass Boston News › Events › Event Date:  October 09, 2014 - 2 p.m.Location:  Campus Center, 1st floor, Room 1313With a force of nearly 3000 synthetic and medicinal chemists, WuXi AppTec is the largest and most experienced chemistry service organization ... [Published University of Massachusetts Boston - Sep 20 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Acyclic nucleoside phosphonate diesters

The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using ... [Published Free Patents Online - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Propargyl substituted nucleoside compounds and methods

Disclosed, among other things, are compounds having the structure wherein X comprises a bond or a linker, LABEL comprises at least one detectable label, W1 taken alone is —H or —OH, W2 is —OH or a non-extendable moiety, W3 when taken alone is —H or when ... [Published Free Patents Online - Sep 16 2014]
Entities: Nucleoside, Moiety
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Scientists discover RNA modifications in some unexpected places

PUBLIC RELEASE DATE: 15-Sep-2014CAMBRIDGE, Mass. (September 15, 2014) – The so-called central dogma of molecular biology—that DNA makes RNA which makes protein—has long provided a simplified explanation for how genetic information is deciphered and translated ... [Published EurekAlert! - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Alios BioPharma : Announces Upcoming RSV & HCV Scientific Presentations

- Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, will be presenting data at several important scientific meetings over the next eight weeks. The company has made significant progress in development ... [Published 4 Traders - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors ...

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine ... [Published 7thSpace - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 2 reports

GlaxoSmithKline's ViiV Healthcare venture earns EU approval for HIV drug

:50 in Pharmaceutical Company Product News GlaxoSmithKline has announced that ViiV Healthcare, its joint venture with Pfizer, has been granted European regulatory approval for a convenient new HIV therapy. The European Commission has granted marketing ... [Published Zenopa - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Nestlé files patent for kids’ ‘protein balance’

Nestlé has filed for a worldwide patent for a protein balancing product aimed at children aged 5-15.The inventors propose that the administration of a specific dose of high quality whey proteins and casein proteins and/or soy-based proteins was effective ... [Published FoodNavigator-Asia.com - Sep 03 2014]
Entities: Protein, Nestlé SA, Patent
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Conformationally constrained nucleoside phosphonic acids - potent inhibitors of human mitochondrial and cytosolic 5[prime or minute](3[prime or minute])-nucleotidases

aInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v. v. i., Flemingovo 2, 166 10 Prague 6, Czech RepublicE-mail: rosenberg@uochb.cas.cz , brynda@img.cas.czbInstitute of Molecular Genetics, of Sciences of the ... [Published RSC - Sep 01 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 1 reports

ViiV gets FDA green light for HIV triple combo

ViiV Healthcare has received the green light from US regulators for its HIV triple combination treatment Triumeq.The joint venture owned by GlaxoSmithKline, Pfizer and Shionogi says the US Food and Drug Administration has approved Triumeq, which combines ... [Published Pharma Times - Aug 25 2014]

Quotes

...According to news reporting originating from Kaifeng, People's Republic of China, by NewsRx correspondents, research stated, "A novel strategy was used in the design of self-assembled drug delivery systems (SADDSs) in this study. The nanoassemblies of an amphiphilic adefovir lipid derivative were prepared and demonstrated to have the functions of hepatocyte targeting, enzyme-triggered drug release and high anti-hepatitis effect."
Cobicistat-boosted atazanavir plus tenofovir emtricitabine "demonstrated durable efficacy through week 144," the investigators concluded. "Once-daily cobicistat is as safe and effective as ritonavir as a pharmacoenhancer of the protease inhibitor atazanavir."
"This is really a better, more quantitative method to measure this modification, which is interesting in and of itself" says Douglas Bernstein, a co-first author of the Cell paper. "Finding the modification in mRNA was an unexpected bonus."
...Lawrence M Blatt, President and Chief Executive Officer of Alios. "The Alios purine and pyrimidine nucleotides AL-516 and AL-335 offer the potential for combination therapy that could be effective against all HCV genotypes, greatly simplifying therapy."

More Content

All (125) | News (111) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (1) | Press Releases (2)
sort by: Date | Relevance
Methods for identifying RNA segments bound by R... [Published Free Patents Online - 35 mins ago]
Metal-Ion-Mediated Base Pairing between Natura... [Published Journal of Organic Chemistry - 15 hours ago]
WuXi AppTec Information Session [Published University of Massachusetts Boston - Sep 20 2014]
The European Medicines Agency grants the "orpha... [Published Vall d'Hebron - Sep 19 2014]
Aberrant methylation of tRNAs links cellular st... [Published EMBO Journal - Sep 17 2014]
Gene Expression and Pathway Analysis of Effects... [Published Plosone.org - Sep 17 2014]
SUDEP Basic Science Mechanisms [Published Noodls - Sep 17 2014]
Avian influenza: The use of antiviral chemotherapy [Published Engormix.com - Sep 17 2014]
Studies from Henan University Yield New Informa... [Published Pharmacy Choice - Sep 17 2014]
Acyclic nucleoside phosphonate diesters [Published Free Patents Online - Sep 16 2014]
Buy The Dip In Gilead: Why A Decrease In Quarte... [Published Seeking Alpha - Sep 16 2014]
Propargyl substituted nucleoside compounds and ... [Published Free Patents Online - Sep 16 2014]
ICAAC 2014: Cobicistat Long-term Efficacy Match... [Published HIV and Hepatitis.com - Sep 16 2014]
Entecavir combined with furin inhibitor simulta... [Published 7thSpace - Sep 16 2014]
Scientists discover RNA modifications in some u... [Published EurekAlert! - Sep 15 2014]
Updated Summary: Antiretroviral therapy. [New Y... [Published National Guideline Clearinghouse - Sep 15 2014]
Alios BioPharma Presents Data on Its Anti-HCV N... [Published RCL Advisors - Sep 15 2014]
Immortality Superfoods Introduce Liquid Gold,... [Published Free Press Release - Sep 12 2014]
Bone Mineral Density Over 96 Weeks in Adults Fa... [Published JAIDS - Sep 11 2014]
Alios BioPharma : Announces Upcoming RSV & HCV ... [Published 4 Traders - Sep 11 2014]
Three-in-one combo gets two green lights [Published Drug Discovery News - Sep 11 2014]
Researchers Submit Patent Application, "Methods... [Published 4 Traders - Sep 10 2014]
Hemispherx Biopharma, USAMRIID Team Up To Evalu... [Published Bioresearch Online - Sep 10 2014]
ViiV Healthcare receives marketing authorizatio... [Published Individual.com - Sep 10 2014]
Modeling interactions between Human Equilibrati... [Published 7thSpace - Sep 10 2014]
Riding Merck: The Conservative Aggressive Pharm... [Published Seeking Alpha - Sep 09 2014]
HIV in Resting CD4 Cells May Contain Antiretrov... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
Dolutegravir Superior to Efavirenz at 144 Weeks... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
Aptose appoints Howell as CMO [Published Stockwatch - Sep 08 2014]
Aptose Biosciences Recruits Stephen B. Howell, ... [Published Reliance Trust - Sep 08 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Comment] Does HIV antiretroviral therapy still... [Published The Lancet online - Aug 05 2014]
Almost 20 years ago, potent combination antiretroviral therapies were introduced and led to unprecedented decreases in HIV-related morbidity and mortality. Nucleoside and nucleotide reverse-transcriptase inhibitors (NtRTIs) became essential additions ...
Forced mutations doom HIV [Published MIT News feed - Jul 28 2014]
Fifteen years ago, MIT professor John Essigmann and colleagues from the University of Washington had a novel idea for an HIV drug. They thought if they could induce the virus to mutate uncontrollably, they could force it to weaken and eventually die ...
TriLink gets patents for new ligation technolog... [Published PBR - News - Jun 20 2014]
TriLink BioTechnologies (TriLink), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, has announced that it has been awarded patents in the US (8,728,725), Europe (EP 2451980) and New Zealand (597535) for their ...
TriLink Awarded Patents for Novel Ligation Tech... [Published Marketwire - Breaking News Releases - Jun 19 2014]
SAN DIEGO, CA--(Marketwired - Jun 19, 2014) - TriLink BioTechnologies ( TriLink ), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, today announced that it has been awarded patents in the US (8,728,725), Europe ...
TriLink to Open New GMP Facility Aimed at Early... [Published Marketwire - Breaking News Releases - May 21 2014]
SAN DIEGO, CA--(Marketwired - May 21, 2014) -  TriLink BioTechnologies ( TriLink ), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, today announced their new 2,000 square foot diagnostic and pharmaceutical ...
1 2 3

Press Releases

sort by: Date | Relevance
QED Connect Inc. Plans to Add World Class Scien... [Published GlobeNewswire: Acquisitions News - Jul 10 2014]
Chimerix Regains Worldwide Rights to CMX157 [Published GlobeNewswire: Advertising News - May 16 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.